NOW APPROVED FOR A NEW INDICATION

Access and savings

VASCEPA is affordable for most patients*

Generic prescriptions may be costing your patients more than you think

PRODUCT AVERAGE OUT-OF-POCKET COST INDICATION FOR REDUCING CV RISK1,2
Generic Lovaza® $25.24 None
Fenofibrate $18.21 None

Average cost to patients with COMMERCIAL insurance in Q3 2019.*

TOP

Prescription VASCEPA delivers proven CV risk reduction at an affordable price3

Commercially insured patients can pay as little as $9 for a 90-day supply with the universal VASCEPA Savings Card.§ Subject to eligibility. Restrictions apply.

VASCEPA Savings Card
  • Most eligible, insured patients will pay as little as $9 of their copayII every 90 days while saving up to $330 per 90-day fill
  • If your patients prefer to get the savings card on a mobile device, instruct them to text "VASCEPA" to 26789. Message and data rates may apply
Get the card

Offer Restrictions: May not be used to obtain prescription drugs paid in part by Federal or State Programs including Medicare, Medicaid, Medicare Advantage, Medicare Part D, Tricare, VA. Most eligible, insured patients will pay as little as $9 of their copay for either each month or a 90 day fill, with a maximum savings of up to $110 per month or $330 on a 90 day fill. Not for use by residents of VT, nor medical professionals licensed in VT. This offer is not valid for those patients under 18 years of age or patients whose plans do not permit use of a copay card. Void where prohibited by law, taxed, or restricted. Eligible patients include those who participate in commercial insurance, through a healthcare exchange, or pay cash. Offer good through December 31, 2020.

§Universal Pharmacy Card (UPC) may be applied for any eligible patient by entering all 4 codes into the notes section of an e-prescription.

TOP

VASCEPA has unrestricted access on most plans regardless of TG level

Graphic icon reading >80% overall unrestricted access and >95% unrestricted access for Medicare Part D patients
  • Overall, patients have >80% unrestricted access||
Graphic icon reading >80% overall unrestricted access and >95% unrestricted access for Medicare Part D patients
  • Medicare Part D patients have >95% unrestricted access||

VASCEPA has been studied in patient populations with TG levels ranging from 200 to 2000 mg/dL.

TOP

Prescribe VASCEPA electronically

Universal Pharmacy Card (UPC) may be applied for any eligible patient by entering all 4 codes into the notes section of an e-prescription.

BIN# 004682

PCN# CN

GRP# ECVASCEPA

ID# 59‍0211‍393‍03

TOP

Low income subsidy (LIS)–qualified beneficiaries receive subsidized benefits#

LIS Medicare beneficiaries have low out-of-pocket prescription expenses (ranging from $0 to $8.35) for drugs such as VASCEPA, with a fixed branded copay that is not subject to a deductible or the coverage gap/donut hole.||

TOP

Mail order rebate form

Give your patients this form to fill out if they obtain their VASCEPA prescription via a mail order program.

Download rebate form
TOP

Discover VASCEPA resources

Get started

Get your patients started, request samples of VASCEPA online

LEARN MORE
 

INDICATIONS AND LIMITATIONS OF Use

  • VASCEPA® (icosapent ethyl) is indicated as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥150 mg/dL) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease
  • VASCEPA is indicated as an adjunct to diet to reduce TG levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia
    The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined

Important Safety Information

  • VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components
  • VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter
  • It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur
  • VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel or warfarin
  • Common adverse reactions in the cardiovascular outcomes trial (incidence ≥3% and ≥1% more frequent than placebo): musculoskeletal pain (4% vs 3%), peripheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%) and atrial fibrillation (5% vs 4%)
  • Common adverse reactions in the hypertriglyceridemia trials (incidence ≥1% more frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%)
  • Adverse events may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088
  • Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents for bleeding should be monitored

Please see full Prescribing Information for more information on VASCEPA.

*Data on file.

Source: Symphony Health Claims Data; November 2019.

IIAs of February 8, 2019.

#Premium, deductible, copay, and drug costs in the coverage gap are reduced or eliminated for LIS beneficiaries.


References: 1. Lovaza [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2019. 2. Department of Health and Human Services. [Docket no. FDA–2016–N–1127]: AbbVie Inc., et al; Withdrawal of approval of indications related to the coadministration with statins in applications for niacin extended-release tablets and fenofibric acid delayed-release capsules. Federal Register. April 18, 2016;81(74):22612-22613. 3. VASCEPA [package insert]. Bridgewater, NJ: Amarin Pharma, Inc.; 2019.

Important Safety Information

  • VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components
  • VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter

INDICATIONS AND LIMITATIONS OF USE

  • VASCEPA® (icosapent ethyl) is indicated as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥150 mg/dL) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease
  • VASCEPA is indicated as an adjunct to diet to reduce TG levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia

    The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined